Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Consumer OTC Drugs

Menley & James entering cough/cold sector with OTC version of Adams Labs' Humibid.

This article was originally published in The Tan Sheet

  • News
  • The Tan Sheet

Executive Summary

MENLEY & JAMES TO ENTER COUGH/COLD SECTOR WITH OTC VERSION OF HUMIBID, a prescription multisymptom product manufactured and sold by Medeva PLC subsidiary Adams Labs. Menley & James announced March 20 that it will begin shipping the OTC product to trade in June; the product will be available regionally in drug stores and mass merchandisers beginning in early fall. The company is targeting nationwide availability by the start of the 1997 cold season.

Table

View full table

Topics

Tags:
Consumer OTC Drugs
Latest Headlines

EU CHMP Opinions And MAA Updates

MHRA Needs ‘Rebuilding’ After Post-Brexit Loss Of Capacity & Industry Investment

EU & South Korea Sign Deal On Exchange Of Confidential Information

Recent And Upcoming FDA Advisory Committee Meetings

See All
UsernamePublicRestriction

Register

PS084921

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By